Lawyers in the Mass Torts Section at Beasley Allen continue to pursue Risperdal claims on behalf of individuals who have been injured as a result of taking Risperdal, the brand name drug manufactured by Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson. The drug went on the market in 1993 after receiving approval from the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia. In 2003, the drug was approved for short term treatment of acute manic/mixed episodes associated with Bipolar I Disorder in adults. Until 2006, the drug was not approved for any indication to treat minors.
In 1997, the FDA denied a request by Janssen for a pediatric indication for the drug. Despite this denial, Janssen marketed the drug for the treatment of depression, anxiety, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), conduct disorder, sleep disorders, anger management and mood enhancement/stabilization.
In 2006, Janssen obtained approval to market the drug for autistic irritability for children and adolescents between the ages of 5 to 16 years old. In 2007, Janssen obtained approval to market the drug for treatment of schizophrenia in adolescents between the ages of 13 to 17 years old and short-term treatment of manic or mixed episodes of Bipolar I Disorder in children and adolescents between the ages of 10 to 17 years old. Use of Risperdal can cause gynecomastia (enlarged breasts in males), galactorrhea (milky nipple discharge), weight gain, hyperglycemia, diabetes and inhibited reproductive function.
In January 2015 the trial judge in Philadelphia ruled that the statute of limitations under Pennsylvania law began to run as of June 30, 2009, for individuals that used Risperdal before October 2006. A statute of limitations is a period of time that is allowed by law for an injured party to pursue claims. Each state has its own statute of limitations for product liability actions and the time period for pursuing claims varies from state to state. The statute of limitations can also vary from state to state on what triggers the statute to begin running and whether the statute of limitations is tolled based on discovery of the injury and/or cause of injury.
The Philadelphia trial judge has indicated that he may enter a case management order that applies the January 2015 ruling to all Risperdal cases pending in Philadelphia. This ruling will be appealed. In the event the January 2015 ruling is upheld, it could have a significant impact on Risperdal cases filed in Philadelphia. The January 2015 ruling may not bar claims for injuries that arose after June 30, 2009, provided the lawsuit was filed within two years of the discovery of the injury.
If you need more information on the Risperdal litigation, contact James Lampkin, a lawyer in our firm’s Mass Torts Section, at 800-898-2034 or by email at James.Lampkin@beasleyallen.com.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.